In Houston, Texas, scientists have uncovered a discovery that could one day help doctors choose the right treatment for men with prostate cancer — faster. Researchers at the University of Texas MD Anderson Cancer Center found that two specific genetic changes in prostate tumors decide whether the cancer will respond well or poorly to a promising new type of therapy called ferroptosis. Their findings, published in the journal Nature Communications, offer a possible roadmap for matching patients with the treatment most likely to work for them.
Ferroptosis is a kind of cell death — think of it as a cleanup process the body can trigger to destroy damaged or abnormal cells. Scientists have been studying whether they can use it to kill cancer cells, but the approach doesn't work for every tumor. This new research helps explain why.
The team, led by Di Zhao, Ph.D., and Boyi Gan, Ph.D., studied two common genetic alterations found in prostate cancers: mutations in a gene called SPOP and deletions in a gene called CHD1. The results were striking — and completely opposite.
When prostate cancers carry SPOP mutations, they become more vulnerable to ferroptosis. That's because the mutation causes an increase in an enzyme called ACSL4, which loads fatty acids into cell membranes — exactly what ferroptosis therapy targets. On the flip side, when tumors have CHD1 deletions, ACSL4 levels drop, making the cancer cells much harder to kill with ferroptosis.
But the researchers didn't stop there. They also found a potential workaround for tumors with CHD1 deletions: statins, the widely-used cholesterol-lowering drugs. In lab experiments, statins helped restore ACSL4 levels in these tumors, essentially sensitizing them to ferroptosis. Since statins are already approved and widely available, this finding could eventually offer a practical way to expand who can benefit from this therapy.
"Prostate cancer is such a genetically diverse cancer that there are many possible treatment options, so getting patients on the right treatment as quickly as possible is crucially important," Zhao said. The hope is that testing for SPOP mutations and CHD1 deletions could one day help doctors know upfront which patients are most likely — or least likely — to respond to ferroptosis-based treatments currently being tested in clinical trials.
While much more research is needed before these findings reach patients, the study represents a meaningful step toward more precise, personalized care for a disease that affects millions of men worldwide.